Drug Trial Radar · NCT01713946
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
Last checked: Nov 19, 2026Latest source record: Nov 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Apr 29, 2013
Primary completion
Oct 25, 2017
Study completion Oct 25, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 25, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\].
Conditions
- Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001Drug
Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
PlaceboDrug
Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Antiepileptic drug (1 to 3 only)Drug
no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
open label RAD001 (only used for post-extension phase)Drug
everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Phase: European Medicine Agency (EMA): Seizure Frequency Response RateTime frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
- Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure FrequencyTime frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Locations
104 sites in 25 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham SC
Birmingham, Alabama
TGen/APNNA
Phoenix, Arizona
University of California at Los Angeles SC
Los Angeles, California
Children's Hospital Oakland SC
Oakland, California
Children's Hospital of Orange County SC
Orange, California
Rady Children's Hospital SC
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Connecticut Childrens Medical Center SC
Hartford, Connecticut
University of Chicago SC - 2
Chicago, Illinois
Kennedy Krieger Institute SC
Baltimore, Maryland
Children's Hospital Boston SC
Boston, Massachusetts
Minnesota Epilepsy Group - PA SC
Saint Paul, Minnesota
Washington University School of Medicine SC-2
St Louis, Missouri
Morristown Memorial Hospital SC-2
Morristown, New Jersey
New York University Medical Center SC-3
New York, New York
Cincinnati Children's Hospital Medical Center SC
Cincinnati, Ohio
Oregon Health and Science University SC - 3
Portland, Oregon
Children's Hospital of Philadelphia SC
Philadelphia, Pennsylvania
LeBonheur Childrens Medical Group SC
Memphis, Tennessee
Texas Scottish Rite Hospital for Children Texas Scottish
Dallas, Texas
Texas Children s Hospital SC
Houston, Texas
The University of Texas Medical School-Houston SC
Houston, Texas
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Randwick, New South Wales, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Jette, Brussels Capital, Belgium
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Medellín, Colombia
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia
Novartis Investigative Site
Aarhus, Denmark
Novartis Investigative Site
Amiens, France
Novartis Investigative Site
Angers, France
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.